JP2009215275A - Oral administration composition containing plant belonging to the genus salacia - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an oral administration composition satisfying both of a sufficient sugar absorption inhibitory effect and the reduction of the symptoms of an abdominal bloating feeling, meteorism and increased flatus, and to provide the oral composition reducing the following symptoms, since there are cases showing the symptoms of the abdominal bloating feeling, meteorism and the increased flatus on taking the composition containing a plant belonging to the genus Salacia depending on constitution, and it is considered to be caused by gases formed by the decomposition and fermentation of the carbohydrates by intestinal bacteria, because by the sugar absorption inhibitory action of the plant belonging to the genus Salacia, un-digested carbohydrates reach to large intestine. <P>SOLUTION: This oral administration composition is provided by containing an extract of the plant belonging to the genus Salacia and a degasifying agent, and preferably containing ≥1 kind selected from the group consisting of a defoaming agent as the degasifying agent, digestive enzyme, plant extract, pigment and gas-adsorption agent. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention relates to an oral composition containing a plant of the genus Salacia.

  The roots and trunks of Salacia plants have been used as natural drugs in traditional medicine Ayurveda in India and Sri Lanka. In Sri Lanka, it is said that the root bark of Salacia reticulata is effective for the treatment of rheumatism, gonorrhea and dermatoses, as well as for the treatment of early stage diabetes. In India, the roots of S. oblonga (S. oblonga) are used for similar treatment, and S. chinensis is also used for the treatment of diabetes (Non-patent Document 1).

Thus, it has been handed down that the plants of the genus Salacia are effective for the prevention and initial treatment of diabetes. In recent years, it has been reported that plants of the genus Salacia have an inhibitory effect on the increase in blood glucose level, and that the mechanism of action is due to an inhibitory action on sugar absorption based on inhibition of α-glucosidase activity (Non-patent Document 1).
Further, it has been reported that Salacia plants contain xanthone glycoside mangiferin (Non-patent Document 2).

  In addition, there are patents (Patent Documents 1 to 3) of compounds having an inhibitory action on α-glucosidase contained in Salacia extract components, and application examples and patents as antidiabetic agents based on an inhibitory action on α-glucosidase. (Patent Documents 4 to 5).

  Ingestion of a composition containing a plant belonging to the genus Salacia may exhibit symptoms such as abdominal bloating, flatulence, and increased paralysis depending on the constitution. This is considered to be due to the gas generated when the undigested sugar reaches the large intestine due to the sugar absorption inhibitory action of the plant belonging to the genus Salacia and is decomposed and fermented by intestinal bacteria. In order to reduce these symptoms, it is conceivable to reduce the content of the plant belonging to the genus Salacia in the composition, but this also reduces the sugar absorption inhibitory action, and a sufficient effect cannot be obtained.

Japanese Patent No. 3030008 JP 2004-323420 A JP 2000-86653 A Japanese Patent Laid-Open No. 9-301882 Japanese Patent No. 3261090 FOOD Style 21, Vol. 6, No. 5, pp. 72-78 YAKUGAKU ZASSHI, 121 (5), 371-378.

  An object of the present invention is to provide an oral composition that achieves both a sufficient sugar absorption inhibitory effect by Salacia plants and a reduction in symptoms of abdominal bloating, flatulence, and increased paralysis.

As a result of intensive studies to solve the above-mentioned problems, it has been found that the symptoms of abdominal fullness, flatulence, and increased paralysis can be reduced by including a degassing agent in the composition containing the extract of the plant of Salacia.
In the present invention, a degassing agent is contained in a composition containing an extract of a Salacia plant, in particular, an extract of a Salacia plant having a high sucrase inhibitory activity (small IC ₅₀ value). It can supply products with high sugar absorption inhibition and few symptoms of abdominal fullness, flatulence, and increased paralysis. Furthermore, by containing lactic acid bacteria and mineral yeast, a product with less symptoms can be supplied.
Specifically, it has the following configuration.
<1>
An oral composition comprising an extract of a plant of the genus Salacia and a degassing agent.
<2>
The oral composition according to <1> above, wherein the content of the extract of the plant of the genus Salacia in the oral composition is an amount that satisfies the following relationship.
0.8 ≦ [daily intake of Salacia plant extract (mg)) / [50% inhibitory concentration of sucrase (μg / ml)]
<3>
The oral composition according to <1> or <2> above, wherein the 50% inhibitory concentration of sucrase in the extract of the plant of Salacia is 10 μg / ml or more and 300 μg / ml or less.
<4>
The oral composition according to any one of <1> to <3> above, wherein 40 mg or more of the extract of the genus Salacia is contained in the daily dose of the oral composition.
<5>
Any one of the above <1> to <4>, wherein the degassing agent is at least one selected from the group consisting of an antifoaming agent, a digestive enzyme, a plant extract, a pigment, and a gas adsorbent. Orally.
<6>
The oral composition according to <4>, wherein the antifoaming agent is silicone.
<7>
The oral composition according to <5>, wherein the silicone is dimethylpolysiloxane.
<8>
The oral composition according to any one of <5> to <7> above, wherein the digestive enzyme is at least one of cellulase and protease.
<9>
The oral composition according to any one of the above <5> to <8>, wherein the plant extract is at least one selected from the group consisting of citrus fruits, Tochu, bitter melon, and ume. .
<10>
The oral composition according to any one of <5> to <9> above, wherein the gas adsorbent is at least one of charcoal and cyclodextrins.
<11>
Furthermore, lactic acid bacteria are contained, Oral composition of any one of said <1>-<9> characterized by the above-mentioned.
<12>
Furthermore, mineral yeast is contained, Oral composition of any one of said <1>-<11> characterized by the above-mentioned.
<13>
The oral composition according to any one of <1> to <12> above, wherein the mineral yeast is chrome yeast.
<14>
The oral composition according to any one of <1> to <13> above, which is a food, a quasi-drug, or a pharmaceutical product.
<15>
The oral composition according to any one of <5> to <14>, wherein the gas adsorbent is a magnesium compound <16>.
The extract of the plant of the genus Salacia contains mangiferin at a concentration of 0.8% by mass or more based on the total amount of the extract, according to any one of the above items <1> to <15>. Oral composition.
<17>
The oral composition according to any one of <1> to <16>, wherein the oral composition contains 1 mg or more of mangiferin in a daily dose <18>
The oral composition according to any one of <1> to <17> above, wherein the oral composition contains 0.20% by mass or more of mangiferin based on the total amount of the oral composition. Composition.

The present invention relates to an extract of a Salacia plant, particularly an oral composition containing an extract of a Salacia plant having a high inhibition activity of enzyme activity and a degassing agent with a sucrase 50% inhibitory concentration (IC ₅₀ value) of 300 μg / ml or less. By using the product, it is possible to obtain a high sugar absorption suppression effect, reduce abdominal bloating, flatulence, and increased symptoms of phlegm, and also promote the body weight suppression effect and improve diarrhea / constipation. is there.

  According to the present invention, a sufficient effect can be obtained by using an oral composition containing an extract of a plant belonging to the genus Salacia having a high sucrase inhibitory activity, and symptoms of increased abdominal bloating, flatulence, and increased fecal conditions can be obtained. This can reduce the burden on the intake.

The plant belonging to the genus Salacia of the present invention is a plant belonging to the family Nymphalaceae that grows mainly in Sri Lanka, India and Southeast Asia. More specifically, Salacia reticulata, Salacia oblonga, Salacia prinoides ( 1 selected from Salacia prinoides, Salacia chinensis, Salacia latifolia, Salacia burunoniana, Salacia grandiflora, Salacia macrosperma More than one type of plant is used.
In the present invention, an extract of a plant belonging to the genus Salacia means a pulverized product, dried product, extract or dried powder (extract powder) of edible parts such as roots, trunks, leaves, flowers and fruits. One or more kinds of sites may be mixed and used. More preferably, extract powder extracted from roots and trunks is used.

The extract powder is obtained by drying the edible portion or the like obtained by solvent extraction. The extraction solvent may be selected from water, alcohols such as methanol and ethanol, or a mixed solvent of water and alcohols or ketones such as acetone. Preferably, water, alcohol or hydrous alcohol is used. More preferably, hot water, ethanol or hydrous ethanol is used as the extraction solvent. The alcohol concentration of the hydrous alcohol may be 30 to 90% by mass, preferably 40 to 70% by mass.
Examples of the drying method include spray drying and freeze drying, but are not limited thereto.

The extract of Salacia plant preferably has a sucrase 50% inhibitory concentration (IC ₅₀ value) of 10 μg / ml or more and 300 μg / ml or less, more preferably 10 μg / ml or more and 200 μg / ml or less, more preferably 10 μg. Those having a viscosity of not less than / ml and not more than 100 μg / ml are particularly preferred.

The sucrase 50% inhibitory concentration (IC ₅₀ value) is measured by the following method.

[Experimental method 1] Measurement of sucrase IC ₅₀ value Preparation of sample solution: Weigh 2 mg of sample into a tube, add 2 mL of water and suspend well to prepare a sample solution having a concentration of 1 mg / mL. This is diluted with water to 0, 50, 100, 250, and 500 μg / mL, respectively.

  Preparation of substrate solution: Sucrose is dissolved in 0.2 M maleate buffer (pH 6.0) to a sucrose concentration of 100 mM, and this is used as a substrate solution.

  Preparation of crude enzyme solution: 1 g of an intestinal acetone powder rat (manufactured by SIGMA) was suspended in 10 mL of physiological saline, followed by centrifugation (3,000 rpm, 4 ° C., 5 min). The obtained supernatant is separated to obtain a crude enzyme solution.

  400 μL of the substrate solution was added to 500 μL of the sample solution having each concentration described above, and pre-warmed at 37 ° C. for 5 minutes in a water bath. 100 μL of the crude enzyme solution was added to each, and reacted at 37 ° C. for 60 minutes. After completion of the reaction, the enzyme was inactivated by heating at 95 ° C. for 2 minutes to stop the reaction. The produced glucose concentration is quantified using a commercially available kit, mutarotase / glucose oxidase method (glucose CII test Wako, Wako Pure Chemical Industries, Ltd.).

  Blank preparation: 200 μL of substrate solution and 50 μL of crude enzyme solution are added to 250 μL of the sample solution of each concentration described above, and the enzyme is heat-inactivated by immediately heating at 95 ° C. for 2 minutes to obtain blank data. .

A calibration curve is prepared from the obtained values, and the concentration at which the enzyme activity is inhibited by 50% (IC ₅₀ value) is determined.

When setting the daily intake or the reference intake of the oral composition, as the amount of the extract of the plant belonging to the genus Salacia in the daily dose of the composition, for example, a Salacia plant having an IC ₅₀ value of 50 μg / ml When using an extract, 10-600 mg is preferable, 40-450 mg is more preferable, and 50-300 mg is especially preferable.
The preferable amount of the plant belonging to the genus Salacia in the oral composition can be appropriately calculated from the preferable amount per day. For example, when a tablet with a daily intake of 3 tablets is prepared, it is preferable to contain 1/3 of the daily dose per tablet. That is, the extract of the plant of the genus Salacia is preferably 3 to 200 mg, more preferably 13 to 150 mg, and particularly preferably 17 to 100 mg.

Moreover, it is preferable that the value calculated | required by following formula 1 is 0.5 or more, It is more preferable that it is 0.8 or more, It is especially preferable that it is 1.7 or more.
The IC ₅₀ value of the oral composition as a whole is preferably 0.1 to 7.5, more preferably 0.15 to 4.50, and particularly preferably 0.3 to 3.75 as the value determined by Formula 2. preferable.
[Formula 1]
Daily intake (mg) / IC ₅₀ value (μg / ml) of Salacia plant extract
[Formula 2]
Oral composition amount (mg) / IC ₅₀ value (μg / ml)

Moreover, it is preferable that the extract of the genus Salacia plant contains mangiferin at a concentration of 0.8% by mass or more with respect to the total amount in the extract, and more preferably 1.0 to 30% by mass. Preferably, it is 3.0-11 mass%, and it is especially preferable.
Mangiferin is preferably contained in an amount of 1 mg or more in the daily dose of the oral composition, more preferably 1.8 mg to 54 mg, and particularly preferably 5.5 to 19 mg.
Moreover, it is preferable that 0.20 mass% or more of mangiferin is contained with respect to the total amount of oral composition, 0.24-7.2 mass% is more preferable, and 0.74-2.5 mass%. Is particularly preferred.

The content of mangiferin can be measured by Experimental Method 2.
[Experiment Method 2] Measurement of Mandiferin Content The content of mangiferin is measured by the following method using HPLC.
<HPLC conditions>
Column: Capcellpack C18 UG120 φ4.6 × 250mm (Shiseido)
Column temperature: 40 ° C
Detection: UV360
Flow rate: 1.0mL / min
Solvent A: 1.0% Acetic acid Solvent B: Methanol Linear gradient (% B): 15% (0min) → 25% (20min)
Samples are prepared by dissolving in 50% methanol and removing insolubles with a syringe filter.
The content is calculated from the detected peak area of mangiferin using a standard curve of the standard.

  The degassing agent used in the present invention has an action of dissipating and removing gas, and is intended for the living body, particularly the intestine.

  Examples of the degassing agent used in the present invention include antifoaming agents, digestive enzymes, plant extracts, pigments, gas adsorbents, gluconate, zinc oxide, and glyoxylic acid. These degassing agents may be used alone or in any combination of two or more.

  Examples of the antifoaming agent used in the present invention include silicone. Silicone is a linear polymer having a siloxane bond as a skeleton, and dimethylpolysiloxane having a methyl group in the side chain (also referred to as polydimethylsiloxane) is preferable. Usually, it can be obtained by hydrolysis and polycondensation of dichlorodimethylsilane and chlorotrimethylsilane. It is preferably harmless to mammals including humans and can be used orally pharmacologically. Specifically, the degree of polycondensation (n) is 20 to 400, preferably 67 to 228, and the viscosity at 25 ° C. is 20 to 1000 cs, preferably 95 to 1050 cs. .

The silicone content is preferably 0.3 to 18.0 parts by weight, more preferably 0.4 to 6.0 parts by weight, and 0.6 to 3.6 parts per 1 part by weight of the extract of the genus Salacia. Part by mass is particularly preferred.
When setting the daily intake or the reference intake of the oral composition, the amount of silicone in the daily dose of the composition is preferably 20 to 700 mg, preferably 60 to 540 mg, particularly 90 to 360 mg. preferable.

  Here, the digestive enzyme broadly means all enzymes involved in digestion. Specifically, peptides and proteins, carbohydrates, lipids, or fibers such as cellulose are used as substrates. For example, proteases that are peptides and proteolytic enzymes, carbohydrolases that are carbohydrate digestive enzymes, lipases that are fat digestive enzymes, and Mention may be made of cellulase which is a fibrin digestive enzyme. Proteases include peptidases that act on polypeptides and proteinases that act directly on proteins, carbohydrolases include polysaccharides that use polysaccharides as substrates, and amylases that use glucosides and oligosaccharides as substrates, and lipases. Also included are phospholipases that use phospholipids as a substrate.

  As the digestive enzyme used in the present invention, those which do not reduce the α-glucosidase inhibitory action of Salacia are preferable, cellulase which is a fibrin digestive enzyme and protease which is a proteolytic enzyme are preferable, and cellulase is more preferable.

  In addition, these digestive enzymes may be used independently and can also be used in combination of 2 or more types arbitrarily.

  These digestive enzymes are not particularly limited by their origin and acquisition method, and may be derived from plants, animals (including humans), microorganisms, etc., and further prepared by genetic engineering techniques. The digestive enzyme is preferably a digestive enzyme that can be administered orally to mammals including humans.

The mixing ratio of the digestive enzyme contained in the composition of the present invention is not particularly limited. For example, when cellulase having an activity of 1,200 to 1,800 u / g is used as an example of the digestive enzyme, 0.3-18.0 mass parts is preferable with respect to 1 mass part of extract, 0.4-6.0 mass parts is more preferable, and 0.6-3.6 mass parts is especially preferable.
When setting the daily intake or the reference intake of the oral composition, the amount of silicone in the daily dose of the composition is preferably 20 to 700 mg, preferably 60 to 540 mg, particularly 90 to 360 mg. preferable.

  Examples of plant extracts used as the degassing agent of the present invention include citrus fruits, Tochu, bitter gourd (also known as bitter gourd, vine moth), ume, rooibos (Aspalathus linearis) aqueous extract obtained from leaves, mushroom fruiting bodies, Examples include persimmon, rice bran, perilla, red beet, seaweed, Japanese oak, Sarno koshikake, gramineous plant extract, sage, rosemary, green tea, etc. ) Fruit, mandarin orange (a kind of citrus fruit), Tochu leaf, bitter melon fruit, and ume fruit.

The plant extract used in the degassing agent of the present invention means a pulverized product such as roots, trunks, leaves, flowers and fruits, a dried product, an extract or a dried powder (extract powder) thereof. One or more kinds of sites may be mixed and used. The preparation of the plant extract can be performed by any method known to those skilled in the art.
When performing solvent extraction of a plant, various solvents can be used as the extraction solvent. Therefore, extraction with an aqueous solvent and extraction with an oily solvent can be performed. However, extraction from an aqueous solvent and / or ethanol is preferable from the viewpoint of safety and the like, and from the viewpoint of extraction efficiency, a heated aqueous solvent is used. More preferably, the extraction is carried out with In the present specification, the aqueous solvent means a solvent containing water, and water alone or a solution obtained by adding a hydrophilic organic solvent to water is also included in the aqueous solvent of the present invention. As the hydrophilic organic solvent, for example, a lower alcohol or lower ketone having 1 to 5 carbon atoms, and a polyhydric alcohol can be used. Specific examples include ethanol, methanol, propyl alcohol, isopropyl alcohol, glycerol, acetone, methyl ethyl ketone, 1,3-butylene glycol, and propylene glycol. Ethanol is preferred as the hydrophilic organic solvent because it has little effect on humans and other animals and the environment even if it remains. Further, in the extraction, other components can be added for reasons such as improving the extraction efficiency.

  The amount of the plant extract used in the present invention varies depending on the type of plant, but when setting the daily intake or the reference intake of the oral composition, the amount of the plant extract in the daily dose of the composition The amount is preferably 10 to 2000 mg, more preferably 20 to 1000 mg, and particularly preferably 50 to 500 mg.

  As the dye used in the degassing agent of the present invention, yellow No. 4, yellow No. 203, yellow No. 202 (1), blue No. 1, cochineal dye, WATER VIOLET 5, Aminyl Yellow E-3GL and CI Reactive Brown 8 Is exemplified. Among these dyes, in particular, yellow No. 4, yellow No. 203, yellow No. 202 (1), blue No. 1 and cochineal dyes are dyes that are highly safe for human bodies and permitted as food addition dyes. It is preferable.

The gas adsorbent used in the degassing agent of the present invention is suitable for oral use, and examples thereof include charcoal, cyclodextrins, magnesium compounds such as magnesium oxide, and other porous materials. Examples of charcoal include white charcoal, bincho charcoal, black charcoal, bamboo charcoal, and activated carbon. Examples of cyclodextrins include α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and cluster dextrin. Examples of the magnesium compound include magnesium oxide, magnesium chloride, magnesium hydroxide, magnesium sulfide, magnesium sulfate, magnesium citrate, magnesium hydrochloride, and magnesium carbonate.
1-50 mass% is preferable with respect to the whole oral composition, 5-35 mass% is more preferable, and, as for content of a magnesium compound, 10-20 mass% is especially preferable. The magnesium compound is preferably contained in an amount of 100 to 200 mg, more preferably 50 to 500 mg, and particularly preferably 10 to 2000 mg in the daily dose of the oral composition. Further, the magnesium compound is preferably contained in an amount of 10 to 200 parts by mass, more preferably 30 to 100 parts by mass, and more preferably 50 to 80 parts by mass with respect to 100 parts by mass of the Salacia extract powder. Particularly preferred.

  The oral composition of the present invention preferably contains lactic acid bacteria. Lactic acid bacteria can be administered orally to mammals including humans, and are preferably bacteria that exhibit useful effects in the living digestive tract.

  More specifically, those that are harmless to the host, are relatively resistant to gastric acid and bile acids, have a fixability in the living intestine, produce lactic acid, and act to regulate the intestinal microflora. desirable. Examples of such useful lactic acid bacteria include Lactobacillus acidophilus, Bifidobacterium longum, etc., Streptococcus faecalis, Lactobacillus reuteri, Lactobacillus casei, and Plantarum. (Lactobacillus plantarum), Fermentum lactobacillus (Lactobacillus fermentum), Lactobacillus rhamnosus, Lactobacillus agilis, Lactobacillus gasseri, Bacillus ricentericum (Bacillus mesentery) Or sub-species thereof, and the like, and preferably Lactobacillus acidophilus, Bifidobacterium longum, and Streptococcus faecalis, and these lactic acid bacteria can be used alone or as a single species. It can be used in combination of two or more as appropriate.

  As long as these lactic acid bacteria are live bacteria, the origin of acquisition is not particularly limited, and those commercially available can be used widely.

  The amount of lactic acid bacteria used in the present invention is 10 million as the number of living lactic acid bacteria in the daily dose of the oral composition when setting the daily intake or the standard intake of the oral composition. To 100 billion, more preferably 50 to 50 billion, and particularly preferably 11 to 10 billion.

The oral composition of the present invention preferably contains mineral yeast. Mineral yeast means yeast containing mineral. As minerals, sodium (Na), potassium (K), chlor (Cl), calcium (Ca), magnesium (Mg), phosphorus (P), sulfur (S), and iron (Fe), zinc called trace elements There are 16 metal elements such as (Zn), copper (Cu), manganese (Mn), cobalt (Co), chromium (Cr), iodine (I), molybdenum (Mo), and selenium (Se). As the mineral yeast used in the present invention, chromium yeast containing chromium is preferable. Although there is no restriction | limiting in particular in the kind of yeast, Baker's yeast or beer yeast is preferable.
The chromium content of the chrome yeast is preferably 0.01 to 5 parts by mass, more preferably 0.05 to 1 part by mass, and particularly preferably 0.1 to 0.3 part by mass with respect to 100 parts by mass of the chrome yeast.
The chrome yeast content in the oral composition is preferably 3 to 5 parts by mass, more preferably 1 to 10 parts by mass, and particularly preferably 0.5 to 50 parts by mass with respect to 100 parts by mass of the oral composition.
When setting the daily intake or the reference intake, the amount of chromium yeast in the daily dose of the oral composition is preferably 5 to 500 mg, more preferably 10 to 100 mg, and particularly preferably 30 to 50 mg. The amount of chromium in the daily dose of the oral composition is preferably 60 to 100 μg, more preferably 40 to 150 μg, and particularly preferably 20 to 200 μg.

  The oral composition of the present invention is intended for mammals including humans and is orally administered to the mammals. The oral composition of the present invention may be a food, quasi drug or pharmaceutical product. Other components include various carriers that are pharmaceutically or food hygienically acceptable for oral administration, such as excipients, lubricants, stabilizers, dispersants, binders, diluents, flavoring agents, sweeteners, A flavoring agent, a coloring agent, etc. can be illustrated.

  The form of the composition of the present invention is not particularly limited as long as it exhibits the effects of the present invention. For example, tablets, pills, granules, fine granules, chewing agents, capsules, liquids, chewables, beverages Etc. Other food forms may be used.

  These dosage forms can be prepared using conventional methods commonly known in the art, but may be prepared under conditions that do not reduce the activity of cellulase or the viable activity of various lactic acid bacteria. desirable.

  In the case of tablets, pills and granules, a dosage form with a conventional coating can be used as necessary, for example, sugar-coated tablets, gelatin encapsulating agents, enteric encapsulating agents, film coating agents and the like. The tablet may be a multilayer tablet such as a double tablet.

  In addition to the above, the oral composition of the present invention includes vitamins, vitamin-like substances, proteins, amino acids, fats and oils, organic acids, carbohydrates, plant-derived materials, animal-derived materials, microorganisms, food additives, and pharmaceutical additives. The ingredient which can be ingested orally can be contained appropriately.

  Hereinafter, the present invention will be described using examples, but the present invention is not limited to the following examples.

(Synthesis Example 1)
After roots and trunks of Salacia reticulata and Salacia oblonga were pulverized, the liquid obtained through the hot water extraction process was spray-dried to obtain Salacia extract powder.
The IC ₅₀ value was measured according to the aforementioned [Experimental method 1] and found to be 50 μg / ml.

(Synthesis Example 2)
1 part by mass of Salacia extract powder obtained in Synthesis Example 1 and 1 part by mass of dextrin were mixed to prepare a diluted Salacia extract powder.
The IC ₅₀ value was measured according to the above [Experiment Method 1] and found to be 103 μg / ml.

(Synthesis Example 3)
1 part by mass of the Salacia extract powder obtained in Synthesis Example 1 and 5 parts by mass of dextrin were mixed to prepare a diluted Salacia extract powder.
The IC ₅₀ value was measured according to the above [Experiment Method 1] and found to be 298 μg / ml.

(Synthesis Example 4)
1 part by mass of Salacia extract powder obtained in Synthesis Example 1 and 7 parts by mass of dextrin were mixed to prepare a diluted Salacia extract powder.
The IC ₅₀ value was measured according to the above [Experiment Method 1] and found to be 397 μg / ml.

(Synthesis Example 5)
Ten males and females aged 25 to 50 years took each intake component listed in Table 1 three times a day before meals for 3 days to examine whether they feel abdominal fullness.
As shown in Table 1, when the daily intake was 240 mg, there was a subject who felt abdominal bloating when the IC ₅₀ value of Salacia extract powder was 300 μg / ml or less. In addition, when the IC ₅₀ value of Salacia extract powder was 50 μg / ml, some subjects felt abdominal bloating when the daily intake was 30 mg or more. Further, there was a subject who felt abdominal bloating when the value of the above-described formula 1 was 0.8 or more. The present invention is preferably used in the case of the IC ₅₀ value and daily intake of a plant of the genus Salacia exhibiting such abdominal fullness.

(Synthesis Example 6)
Shikuwasa fruit (including flesh and pericarp) produced in Okinawa was pulverized, extracted with hydrous ethanol (containing 50 wt% water) and spray-dried to obtain Sikhwaser fruit extract.

(Synthesis Example 7)
An orange fruit extract was obtained by replacing the seeker of Synthesis Example 6 with an orange from Kagoshima Prefecture.

(Synthesis Example 8)
Ume fruits (including flesh and pericarp) from Wakayama Prefecture were crushed, extracted with hot water and spray-dried to obtain a ume fruit extract.

(Synthesis Example 9)
The ume of Synthesis Example 8 was replaced with bitter gourd from Okinawa Prefecture to obtain bitter gourd fruit extract.

(Synthesis Example 10)
The ume fruit of Synthesis Example 8 was replaced with a bamboo leaf produced in Nagano Prefecture to obtain a bamboo leaf extract.

(Prescription Example 1)
Tablets of 3 tablets per day were prepared according to the formulations described in Tables 2 to 4 (that is, 1 tablet contains 1/3 of the daily dose). The raw materials used are shown below. The unit of the numbers is mg. As the Salacia extract powder, the one prepared in Synthesis Example 1 was used.
Dimethylpolysiloxane ... Cellulase manufactured by Toray Dow Corning Co., Ltd. Cellulase A "Amano" 3, Amano Enzyme Co., Ltd. Chrome yeast ... LALLEMAND BIO-INGREDIENTS (containing 0.2 mass% or more of chromium) LALLEMAND Co., Ltd. Acidophilus "Amanophilus" 100 (Bacteria count: 10 billion / g or more) Amenoenzyme-produced fecalis ... Active lactic acid bacteria 100 (Bacteria: 10 billion / g or more) Amano Enzyme-made Bifidobacterium ... Bifido "Amano" 100 (Bacteria: 100 (Billion / g or more) Amano Enzyme Co., Ltd. Crystalline Cellulose… “Zeoras” FD-101 Asahi Kasei Chemicals Co., Ltd. Charcoal…

Examples and Comparative Examples Evaluation 1
The tablets prepared in Formulation Example 1 were taken 3 times a day for 3 days before meals by 10 men and women who had abdominal bloating by ingesting Salacia extract powder. Compared to the case of taking only Salacia extract powder and excipient (prescription 1), the abdominal fullness was scored according to the following criteria, and the average score of 10 people was listed in Table 5 as the degree of reduction. At the same time, constipation or diarrhea was scored according to the following criteria.

No change ... 0 point Slightly reduced ... 1 point Reduced ... 2 points Almost disappeared ... 3 points

As shown in Table 5, by adding various degassing agents to the oral composition containing Salacia extract powder (prescription 2 to 10), abdominal fullness compared with the case where no degassing agent is contained (prescription 1) The symptoms were reduced.
Moreover, the abdominal fullness was further reduced by further containing lactic acid bacteria (formulations 12 to 20). When only lactic acid bacteria were blended without containing a degassing agent (formulation 11), the degree of reduction was small.
Moreover, the abdominal fullness was further reduced by containing chrome yeast in addition to a degassing agent (prescription 22-30). When only chrome yeast was blended without containing a degassing agent (Formulation 21), the degree of reduction was small.

  Furthermore, subjects who exhibit symptoms of constipation or diarrhea when ingesting a composition containing only Salacia extract powder and an excipient (formulation 1) are also suitable for the composition of the present invention (formulations 2 to 10, 12 to 20, 22). Ingesting ˜30) improved the symptoms with the same tendency as abdominal fullness.

Examples and Comparative Examples Evaluation 2
Evaluation The subject 1 further took a tablet of each formulation for a total of one month, and the body weight before and after drinking was measured. Relative value when the rate of weight loss when ingesting each prescription is [(weight after ingestion-weight before ingestion) / weight before ingestion], and the rate of weight loss when ingesting prescription 1 is 100 Table 6 shows the degree of weight loss.

  Compared to the comparative examples (formulations 1, 11, and 21), the weight loss was increased in the present invention. Surprisingly, it was found that the diet effect of the Salacia extract powder is enhanced by the present invention.

(Prescription example 2)
Three tablets per day were made with the formulation described in Table 7 (ie, one tablet contains 1/3 of the daily dose). The raw materials used are shown below. The unit of the numbers is mg. As the Salacia extract powder, the one prepared in Synthesis Example 1 was used.
Magnesium oxide ... Food additive Magnesium oxide (heavy) Magnesium chloride manufactured by Tomita Pharmaceutical ... Food additive Magnesium chloride (hexahydrate) Magnesium sulfate manufactured by Tomita Pharmaceutical ... Food additive Magnesium sulfate (trihydrate) manufactured by Tomita Pharmaceutical

Examples and Comparative Examples Evaluation 3
Take the tablets of Formulation 1, Formula 11, Formula 21 and the tablets prepared in Formulation Example 2 (Formulations 31-39) 3 times a day for 3 days before meals to 10 men and women who have abdominal bloating by taking Salacia extract powder I was asked to. In comparison with the case of ingesting only Salacia extract powder and excipient (prescription 1), the abdominal fullness was scored according to the following criteria, and the average score of 10 people was listed in Table 8 as the degree of reduction. At the same time, constipation or diarrhea was scored according to the following criteria. The results are shown in Table 8.

No change ... 0 point Slightly reduced ... 1 point Reduced ... 2 points Almost disappeared ... 3 points

As shown in Table 8, by including a magnesium compound in an oral composition containing Salacia extract powder (Formulations 31 to 33), the symptoms of abdominal fullness were observed compared to the case where no magnesium compound was contained (Formulation 1). Reduced.
Moreover, the abdominal fullness was further reduced by further containing lactic acid bacteria (formulations 34 to 36). When only a lactic acid bacterium was blended without containing a magnesium compound (formulation 11), the degree of reduction was small.
Moreover, the abdominal fullness was further reduced by containing chromium yeast in addition to the magnesium compound (formulations 37 to 39). When only chrome yeast was blended without containing a magnesium compound (Formulation 21), the degree of reduction was small.

  Furthermore, a subject who exhibits symptoms of constipation or diarrhea when ingesting a composition containing only Salacia extract powder and an excipient (prescription 1) can also ingest the composition of the present invention (prescription 31 to 39). The symptoms improved with the same tendency as abdominal fullness.

Examples and Comparative Examples Evaluation 4
Evaluation The test subjects 3 were further ingested tablets of each formulation for a total of one month, and the body weights before and after drinking were measured. Relative value when the rate of weight loss when ingesting each prescription is [(weight after ingestion-weight before ingestion) / weight before ingestion], and the rate of weight loss when ingesting prescription 1 is 100 Table 9 shows the weight loss.

  Compared to the comparative examples (formulations 1, 11, and 21), the weight loss was increased in the present invention. Surprisingly, it was found that the diet effect of the Salacia extract powder is enhanced by the present invention.

  The Mangiferin content of the Salacia extract powder obtained in Synthesis Example 1 was measured according to [Experiment Method 2] and found to be 0.83% by mass.

(Synthesis Example 11)
After pulverizing the roots and stems of 0.5 kg of Salacia chinensis and 0.5 kg of Salacia prinoides, add 10 L of water and extract under conditions of 100 ° C. for 1 hour. The extract was filtered through a 100 mesh filter and spray-dried to obtain 50 g of extract powder.
The IC ₅₀ value was measured according to the aforementioned [Experiment Method 1] and found to be 49 μg / ml.
It was 1.0 mass% when the mangiferin content of this Salacia extract powder was measured according to [Experimental method 2].

(Synthesis Example 12)
After pulverizing 0.5 kg of Salacia chinensis and 0.5 kg of Salacia prinoides in a different lot from Synthesis Example 11, 10 L of water was added and the mixture was added at 100 ° C. for 1 hour. Extraction was performed under conditions, and the resulting extract was filtered through a 100-mesh filter and spray-dried to obtain 50 g of extract powder.
The IC ₅₀ value was measured according to the aforementioned [Experimental method 1] and found to be 50 μg / ml.
The Mangiferin content of this Salacia extract powder was measured according to [Experiment Method 2] and found to be 3.1% by mass.

(Synthesis Example 13)
After pulverizing 0.5 kg of Salacia chinensis and 0.5 kg of Salacia prinoides in the same lot as in Synthesis Example 11, 10 L of ethanol-containing water (containing 50% by mass of ethanol) The mixture was extracted at 30 ° C. for 1 hour, and the resulting extract was filtered through a 100 mesh filter and spray-dried to obtain 50 g of extract powder.
The IC ₅₀ value was measured according to the aforementioned [Experimental method 1] and found to be 50 μg / ml.
The Mangiferin content of this Salacia extract powder was measured according to [Experiment Method 2] and found to be 10.1% by mass.

(Synthesis Example 14)
After pulverizing 0.5 kg of Salacia chinensis and 0.5 kg of Salacia prinoides in the same lot as in Synthesis Example 12, 10 L of ethanol was added to the mixture at 30 ° C. for 1 hour. Extraction was performed under conditions, and the resulting extract was filtered through a 100-mesh filter and spray-dried to obtain 50 g of extract powder.
The IC ₅₀ value was measured according to the aforementioned [Experiment Method 1] and found to be 49 μg / ml.
When the mangiferin content of this Salacia extract powder was measured according to [Experimental method 2], it was 29.8% by mass.

(Prescription Example 3)
Using the Salacia extract powder prepared in Synthesis Example 11, Synthesis Example 12, Synthesis Example 13 and Synthesis Example 14, tablets were prepared in the same manner as in the above formulations 1-10 and 31-33. "Prescription 1-A" to "Prescription 10-A", "Prescription 31-A" to "Prescription 33-A" using the Salacia extract powder of Synthesis Example 11 and the Salacia extract powder of Synthesis Example 12 were used. "Prescription 1-B" to "Prescription 10-B", "Prescription 31-B" to "Prescription 33-B", and those using the Salacia extract powder of Synthesis Example 13 are "Prescription 1-C" to " “Prescription 10-C”, “Prescription 31-C” to “Prescription 33-C”, and those using the Salacia extract powder of Synthesis Example 14 are “Prescription 1-D” to “Prescription 10-D”, “Prescription 31-”. D ”to“ Prescription 33-D ”. The mangiferin content (calculated value) of each tablet is shown in Tables 10-14.

Examples and Comparative Examples Evaluation 5
About the tablet produced in the prescription example 3, it evaluated about the reduction | decrease degree (abdominal fullness, constipation, or diarrhea) and the weight loss degree similarly to the evaluations 1-4. The results of Evaluation 1 to 4 are shown in Table 10 again, and the results of Evaluation 5 are shown in Tables 11 to 14.

  From Evaluation No. 5, there was no significant change in the degree of reduction (abdominal fullness, constipation or diarrhea) depending on the mangiferin content of the Salacia extract powder and the mangiferin content of the oral composition. The degree of weight loss is determined by using a Salacia extract powder having a mangiferin content of 1.0% by mass or more, and by making an oral composition having a mangiferin content of 1.8 mg / day or more, By using an oral composition having a mangiferin content of 0.24% by mass, and by making an oral composition having a mangiferin content of 5.6 to 18.2 mg per day, The diet effect was large. In particular, a diet effect is obtained by using a salacia extract powder having a mangiferin content of 3.1 to 10.1% by mass and an oral composition having a mandiferin content of 0.74 to 2.42% by mass. Was big.

Claims (18)

  An oral composition comprising an extract of a plant of the genus Salacia and a degassing agent. The oral composition according to claim 1, wherein the content of the extract of the plant of the genus Salacia in the oral composition is an amount satisfying the following relationship.
0.8 ≦ [daily intake of Salacia plant extract (mg)) / [50% inhibitory concentration of sucrase (μg / ml)]   The oral composition according to claim 1 or 2, wherein the 50% inhibitory concentration of sucrase in the extract of the plant of Salacia is 10 µg / ml or more and 300 µg / ml or less.   The oral composition according to any one of claims 1 to 3, wherein the daily dose of the oral composition contains 40 mg or more of a Salacia plant extract.   The said degassing agent is 1 or more types chosen from the group which consists of an antifoamer, a digestive enzyme, a plant extract, a pigment | dye, and a gas adsorbent, The one in any one of Claims 1-4 characterized by the above-mentioned. Oral composition.   The oral composition according to claim 5, wherein the antifoaming agent is silicone.   The oral composition according to claim 6, wherein the silicone is dimethylpolysiloxane.   The oral composition according to any one of claims 5 to 7, wherein the digestive enzyme is at least one of cellulase and protease.   The composition for oral use according to any one of claims 5 to 8, wherein the plant extract is at least one selected from the group consisting of citrus fruits, Tochu, bitter melon and ume.   The oral composition according to any one of claims 5 to 9, wherein the gas adsorbent is at least one of charcoal and cyclodextrins.   Furthermore, lactic acid bacteria are contained, The composition for oral administration of any one of Claims 1-10 characterized by the above-mentioned.   Furthermore, mineral composition is contained, The composition for oral administration of any one of Claims 1-11 characterized by the above-mentioned.   The oral composition according to any one of claims 1 to 12, wherein the mineral yeast is chrome yeast.   The composition for oral administration according to any one of claims 1 to 13, which is a food, a quasi-drug or a pharmaceutical product.   15. The oral composition according to any one of claims 3 to 14, wherein the gas adsorbent is a magnesium compound.   The oral extract according to any one of claims 1 to 15, wherein the extract of the genus Salacia contains mangiferin at a concentration of 0.8% by mass or more based on the total amount of the extract. Composition.   The oral composition according to any one of claims 1 to 16, wherein 1 mg or more of mangiferin is contained in the daily dose of the oral composition.   The oral composition according to any one of claims 1 to 17, wherein the oral composition contains 0.20% by mass or more of mangiferin based on the total amount of the oral composition.